Literature DB >> 1994918

The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study.

D Duboc1, A Kahan, B Maziere, C Loc'h, C Crouzel, C J Menkès, B Amor, G Strauch, F Guérin, A Syrota.   

Abstract

We assessed the effect of nifedipine on myocardial perfusion and metabolism in 9 patients with systemic sclerosis, using positron emission tomography with a perfusion tracer (potassium-38) and a metabolic tracer (18F-fluorodeoxyglucose [18FDG]). Nifedipine, 20 mg 3 times daily for 1 week, induced a significant increase in 38K myocardial uptake, a significant decrease in 18FDG myocardial uptake, and a significant increase in the myocardial 38K: 18FDG ratio. These results indicate that the increase in myocardial perfusion is associated with modifications in myocardial energy metabolism, which probably result from a beneficial anti-ischemic effect of nifedipine in patients with systemic sclerosis.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1994918     DOI： 10.1002/art.1780340211

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


  12 in total

1.  Increased capillary permeability in systemic sclerosis: help or hindrance?

Authors:  W Grassi; P Core; C Cervini
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

Review 2.  Current therapy of systemic sclerosis (scleroderma).

Authors:  U Müller-Ladner; K Benning; B Lang
Journal:  Clin Investig       Date:  1993-04

3.  Scleroderma heart disease: an unusual cause of positive antimyosin cardiac imaging.

Authors:  J Lekakis; M Mavrikakis; V Prassopoulos; S Gerali; N Sifakis; P Kostamis; S Stamatelopoulos
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

4.  Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis.

Authors:  O Vignaux; Y Allanore; C Meune; O Pascal; D Duboc; S Weber; P Legmann; A Kahan
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

Review 5.  Update on assessment and management of primary cardiac involvement in systemic sclerosis.

Authors:  Vasiliki-Kalliopi Bournia; Christos Tountas; Athanase D Protogerou; Stylianos Panopoulos; Sophie Mavrogeni; Petros P Sfikakis
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

6.  Influence of nifedipine on plasma membrane fluidity and oxidative burst of polymorphonuclear leucocytes.

Authors:  W Grassi; R Serretti; P Core; S Muti; C Cervini
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

7.  Left ventricular wall thickness and disease duration in systemic sclerosis.

Authors:  I Hegedüs; L Czirják
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

Review 8.  The heart in systemic sclerosis.

Authors:  Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

9.  Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1.

Authors:  Yannick Allanore; Didier Borderie; Hervé Lemaréchal; Ohvanesse Garabed Ekindjian; André Kahan
Journal:  Arthritis Res Ther       Date:  2004-05-12       Impact factor: 5.156

10.  Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis.

Authors:  Yannick Allanore; Didier Borderie; Axel Périanin; Hervé Lemaréchal; Ohvanesse Garabed Ekindjian; André Kahan
Journal:  Arthritis Res Ther       Date:  2004-11-16       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.